Sanofi-Aventis looks to Acomplia for heart disease treatment

11/16/2004 | NYTimes.com

The company said its drug, already touted for fighting obesity and smoking, has shown promise in improving cholesterol and other heart disease factors, and a Sanofi-Aventis vice president said the company will soon start studies in those areas. Dr. Douglas Greene also outlined the first details of Acomplia's safety and side effects, including a doubled risk of depression.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL